Hualan Bio's H1 2024 revenue grew 4.26% year-over-year, but net profit fell 16.42% due to vaccine sales decline and cost pressures. Blood products remained strong, while vaccine pricing was adjusted to drive future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.